Gilead Sciences Inc (GILD): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Gilead ( GILD) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.8%. By the end of trading, Gilead rose $1.59 (3.0%) to $54.47 on average volume. Throughout the day, 14,304,039 shares of Gilead exchanged hands as compared to its average daily volume of 11,283,900 shares. The stock ranged in a price between $52.93-$55.09 after having opened the day at $53.12 as compared to the previous trading day's close of $52.88. Other companies within the Health Care sector that increased today were: Theragenics Corporation ( TGX), up 36.2%, Alimera ( ALIM), up 27.3%, Opexa Therapeutics ( OPXA), up 26.0% and Unilife Corporation ( UNIS), up 25.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $80.5 billion and is part of the drugs industry. The company has a P/E ratio of 29.5, above the S&P 500 P/E ratio of 17.7. Shares are up 43.7% year to date as of the close of trading on Friday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, increase in net income and growth in earnings per share. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, Genvec ( GNVC), down 33.6%, Electromed ( ELMD), down 11.1%, Redhill Biopharma ( RDHL), down 7.9% and American Shared Hospital Services ( AMS), down 7.5% , were all laggards within the health care sector with Hospira ( HSP) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.